PE20091713A1 - Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos - Google Patents
Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodosInfo
- Publication number
- PE20091713A1 PE20091713A1 PE2008001959A PE2008001959A PE20091713A1 PE 20091713 A1 PE20091713 A1 PE 20091713A1 PE 2008001959 A PE2008001959 A PE 2008001959A PE 2008001959 A PE2008001959 A PE 2008001959A PE 20091713 A1 PE20091713 A1 PE 20091713A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- macrophagus
- ron
- receptor
- inhibition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
REFERIDA A UN ANTICUERPO O FRAGMENTO DE ANTICUERPO QUE SE UNE ESPECIFICAMENTE A UNA PROTEINA RON (PROTEINA ESTIMULANTE DEL MACROFAGO) QUE COMPRENDE UNA CDR SELECCIONADA DE SEQ ID NO: 17; SEQ ID NO 19; SEQ ID NO 21; SEQ ID NO 23, SEQ ID NO 25, SEQ ID NO 27, SEQ ID NO 29, SEQ ID NO 31, SEQ ID NO 33, SEQ ID NO 35, SEQ ID NO 37 Y SEQ ID NO 39. TAMBIEN ESTA REFERIDA A UN VECTOR RECOMBINANTE, UNA CELULA HUESPED Y A UNA COMPOSICION FARMACEUTICA. DICHOS ANTICUERPOS SON UTILES EN EL TRATAMIENTO DEL CANCER
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98955807P | 2007-11-21 | 2007-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20091713A1 true PE20091713A1 (es) | 2009-11-13 |
Family
ID=40364492
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2008001959A PE20091713A1 (es) | 2007-11-21 | 2008-11-24 | Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos |
Country Status (20)
Country | Link |
---|---|
US (2) | US7947811B2 (es) |
EP (1) | EP2222703A2 (es) |
JP (1) | JP5324593B2 (es) |
KR (1) | KR101227338B1 (es) |
CN (1) | CN101868478B (es) |
AR (1) | AR069393A1 (es) |
AU (1) | AU2008330089B2 (es) |
BR (1) | BRPI0820218A2 (es) |
CA (1) | CA2706583A1 (es) |
CL (1) | CL2008003449A1 (es) |
EA (1) | EA018717B1 (es) |
IL (1) | IL204743A (es) |
MX (1) | MX2010005651A (es) |
NZ (1) | NZ584271A (es) |
PA (1) | PA8804901A1 (es) |
PE (1) | PE20091713A1 (es) |
TW (1) | TWI417106B (es) |
UA (1) | UA99633C2 (es) |
UY (1) | UY31478A1 (es) |
WO (1) | WO2009070294A2 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ565511A (en) | 2005-07-22 | 2011-03-31 | Five Prime Therapeutics Inc | Compositions and methods of treating disease with FGFR fusion proteins |
WO2009094148A2 (en) * | 2008-01-22 | 2009-07-30 | Biogen Idec Ma Inc. | Ron antibodies and uses thereof |
EP2265270A1 (en) | 2008-02-04 | 2010-12-29 | OSI Pharmaceuticals, Inc. | 2-aminopyridine kinase inhibitors |
AR070317A1 (es) | 2008-02-06 | 2010-03-31 | Osi Pharm Inc | Furo (3,2-c) piridina y tieno (3,2-c) piridinas |
TWI480050B (zh) * | 2009-02-10 | 2015-04-11 | Daiichi Sankyo Co Ltd | 抗-mst1r抗體及其用途 |
SI2519543T1 (sl) * | 2009-12-29 | 2016-08-31 | Emergent Product Development Seattle, Llc | Beljakovine, ki se vežejo s heterodimeri in njihova uporaba |
JP2013533746A (ja) | 2010-07-06 | 2013-08-29 | アベオ ファーマシューティカルズ, インコーポレイテッド | 抗ron抗体 |
US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
US8951972B2 (en) * | 2010-12-09 | 2015-02-10 | Five Prime Therapeutics, Inc. | FGFR1 extracellular domain combination therapies for lung cancer |
KR20140059168A (ko) * | 2011-04-21 | 2014-05-15 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | 시신경 척수염 치료용 조성물 및 치료 방법 |
CN103857700A (zh) | 2011-08-26 | 2014-06-11 | 梅里麦克制药股份有限公司 | 串联fc双特异性抗体 |
AU2012318247B2 (en) | 2011-11-14 | 2015-12-17 | Five Prime Therapeutics, Inc. | Methods of treating cancer |
MX2015006750A (es) * | 2012-11-30 | 2015-08-05 | Genentech Inc | Composiciones ron y metodos de uso de las mismas. |
CA2896259A1 (en) * | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Anti-mcsp antibodies |
US9458245B2 (en) | 2013-03-06 | 2016-10-04 | Merrimack Pharmaceuticals, Inc. | ANTI-C-MET tandem Fc bispecific antibodies |
JP6779858B2 (ja) * | 2014-07-29 | 2020-11-04 | ウェルマーカー バイオ カンパニー リミテッド | Egfr−標的製剤に対する感受性予測用の新規なバイオマーカー及びその用途 |
US11946934B2 (en) * | 2014-09-03 | 2024-04-02 | Wellmarker Bio Co., Ltd. | Biomarker for predicting the sensitivity to a protein kinase inhibitor and a use thereof |
WO2018038684A1 (en) * | 2016-08-26 | 2018-03-01 | Agency For Science, Technology And Research | Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof |
WO2018052789A1 (en) | 2016-09-08 | 2018-03-22 | Pcm Targetech, Llc | Monoclonal antibodies specific to the plexin-semaphorin-integrin (psi) domain of ron for drug delivery and its application in cancer therapy |
US20220372125A1 (en) * | 2019-10-02 | 2022-11-24 | Aslan Pharmaceuticals Pte. Ltd. | Antigen Specific Binding Domains and Antibody Molecules |
EP4214229A1 (en) * | 2020-09-15 | 2023-07-26 | Duke University | Coronavirus antibodies and uses thereof |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4275149A (en) * | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
ATE120761T1 (de) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
CA2083401C (en) | 1991-02-22 | 2003-03-25 | Bruce I. Terman | Identification of a novel human receptor tyrosine kinase gene |
DK1024191T3 (da) | 1991-12-02 | 2008-12-08 | Medical Res Council | Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker |
AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
US5861301A (en) * | 1992-02-20 | 1999-01-19 | American Cayanamid Company | Recombinant kinase insert domain containing receptor and gene encoding same |
EP2295415A1 (en) | 1995-03-30 | 2011-03-16 | OSI Pharmaceuticals, Inc. | Quinazoline derivatives |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
EP1299419A2 (en) * | 2000-05-24 | 2003-04-09 | Imclone Systems, Inc. | Bispecific immunoglobulin-like antigen binding proteins and method of production |
JP2004527456A (ja) | 2000-08-09 | 2004-09-09 | イムクローン システムズ インコーポレイティド | Egf受容体拮抗剤による過増殖性の疾患の治療 |
SE518548C2 (sv) | 2001-04-11 | 2002-10-22 | Sca Hygiene Prod Ab | Absorberande alster med förbättrad diskretion |
US7235523B2 (en) * | 2001-04-13 | 2007-06-26 | Children's Hospital Medical Center | Methods for the treatment of hepatic disorders |
IL159177A0 (en) | 2001-06-20 | 2004-06-01 | Prochon Biotech Ltd | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
ATE475431T1 (de) | 2002-03-04 | 2010-08-15 | Imclone Llc | Kdr-spezifische humane antikörper und deren anwendung |
US20040101920A1 (en) * | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
US20040185506A1 (en) * | 2003-03-21 | 2004-09-23 | Heavner George A. | Epitope mapping using nuclear magnetic resonance |
WO2005016970A2 (en) | 2003-05-01 | 2005-02-24 | Imclone Systems Incorporated | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
WO2005120557A2 (en) * | 2004-05-13 | 2005-12-22 | Imclone Systems Incorporated | Inhibition of macrophage-stimulating protein receptor (ron) |
-
2008
- 2008-11-20 CL CL2008003449A patent/CL2008003449A1/es unknown
- 2008-11-20 UY UY31478A patent/UY31478A1/es not_active Application Discontinuation
- 2008-11-20 AR ARP080105061A patent/AR069393A1/es not_active Application Discontinuation
- 2008-11-21 US US12/313,589 patent/US7947811B2/en not_active Expired - Fee Related
- 2008-11-21 NZ NZ584271A patent/NZ584271A/en not_active IP Right Cessation
- 2008-11-21 MX MX2010005651A patent/MX2010005651A/es active IP Right Grant
- 2008-11-21 CA CA2706583A patent/CA2706583A1/en not_active Abandoned
- 2008-11-21 AU AU2008330089A patent/AU2008330089B2/en not_active Ceased
- 2008-11-21 EP EP08854059A patent/EP2222703A2/en not_active Withdrawn
- 2008-11-21 JP JP2010534977A patent/JP5324593B2/ja not_active Expired - Fee Related
- 2008-11-21 WO PCT/US2008/013130 patent/WO2009070294A2/en active Application Filing
- 2008-11-21 PA PA20088804901A patent/PA8804901A1/es unknown
- 2008-11-21 KR KR1020107011065A patent/KR101227338B1/ko not_active IP Right Cessation
- 2008-11-21 CN CN2008801172313A patent/CN101868478B/zh not_active Expired - Fee Related
- 2008-11-21 EA EA201070636A patent/EA018717B1/ru not_active IP Right Cessation
- 2008-11-21 BR BRPI0820218-4A patent/BRPI0820218A2/pt not_active IP Right Cessation
- 2008-11-21 TW TW097145251A patent/TWI417106B/zh not_active IP Right Cessation
- 2008-11-21 UA UAA201006208A patent/UA99633C2/ru unknown
- 2008-11-24 PE PE2008001959A patent/PE20091713A1/es not_active Application Discontinuation
-
2010
- 2010-03-25 IL IL204743A patent/IL204743A/en not_active IP Right Cessation
- 2010-12-14 US US12/967,241 patent/US8133489B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2009070294A2 (en) | 2009-06-04 |
AU2008330089A1 (en) | 2009-06-04 |
JP2011504176A (ja) | 2011-02-03 |
BRPI0820218A2 (pt) | 2015-06-23 |
TWI417106B (zh) | 2013-12-01 |
PA8804901A1 (es) | 2009-06-23 |
US20110135631A1 (en) | 2011-06-09 |
TW200936161A (en) | 2009-09-01 |
US7947811B2 (en) | 2011-05-24 |
EP2222703A2 (en) | 2010-09-01 |
UA99633C2 (ru) | 2012-09-10 |
KR101227338B1 (ko) | 2013-01-28 |
CL2008003449A1 (es) | 2010-02-19 |
EA018717B1 (ru) | 2013-10-30 |
US8133489B2 (en) | 2012-03-13 |
UY31478A1 (es) | 2009-07-17 |
CN101868478A (zh) | 2010-10-20 |
IL204743A0 (en) | 2010-11-30 |
CA2706583A1 (en) | 2009-06-04 |
NZ584271A (en) | 2012-05-25 |
AU2008330089B2 (en) | 2013-09-05 |
AR069393A1 (es) | 2010-01-20 |
CN101868478B (zh) | 2013-11-13 |
US20090136510A1 (en) | 2009-05-28 |
IL204743A (en) | 2013-10-31 |
KR20100074293A (ko) | 2010-07-01 |
WO2009070294A3 (en) | 2009-08-20 |
EA201070636A1 (ru) | 2010-10-29 |
JP5324593B2 (ja) | 2013-10-23 |
MX2010005651A (es) | 2010-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20091713A1 (es) | Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos | |
PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
PE20120431A1 (es) | Anticuerpo antagonista para el tratamiento del cancer | |
AR060017A1 (es) | Composiciones y metodos de uso para anticuerpos de dickkopf -1 | |
PE20110225A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 | |
CY1115572T1 (el) | Αντι cxcr4 αντισωματα και χρηση αυτων για τη θεραπεια καρκινου | |
PE20091196A1 (es) | Anticuerpos contra el vegf completamente humano, composiciones y metodos | |
PE20091163A1 (es) | Anticuerpos para gdf8 | |
ATE502052T1 (de) | Monoklonale antikörper gegen den humanen anti- müllerian-hormonrezeptor vom typ ii (amhr-ii) | |
EA201100546A1 (ru) | Полипептиды, вариабельные домены антител и антагонисты | |
PE20121129A1 (es) | Anticuerpos humanos de alta afinidad para la angiopoyetina-2 humana | |
MX2009002711A (es) | Anticuerpos anti-receptor de folato alfa humanos y fragmentos de anticuerpo para la radioinmunoterapia de carcinoma de ovario. | |
PE20130207A1 (es) | Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones | |
CL2012000914A1 (es) | Anticuerpos monoclonales que se unen especificamente a la region c-terminal de progastrina. uso para la preparacion de un medicamento util en el tratamiento de cancer colorectal. | |
UA95068C2 (uk) | Антиген-зв'язуюча молекула, яка зв'язує еgfr, вектор, що її кодує, та їх застосування | |
PE20091193A1 (es) | Proteinas humanas de union a antigenos del gm-csf | |
UA106194C2 (ru) | Диагностика и лечение рака с применением антитела к ereg | |
PE20180502A1 (es) | Composiciones anti-cgrp y uso de las mismas | |
EA200970210A1 (ru) | Prlr-специфическое антитело и его применения | |
AR074360A1 (es) | Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion | |
EA201170590A1 (ru) | Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения | |
WO2012135854A3 (en) | T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2 | |
PE20110306A1 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) | |
CL2008003527A1 (es) | Conjugado de anticuerpo o porcion de union de antigeno del mismo, que se une a la proteina tirosina quinasa 7 (ptk-7/cck4); composicion que lo comprende; acido nulceico cidificante del anticuerpo; vector y celula huesped; uso del conjugado para tratar o prevenir una enfermedad de celulas tumorales que expresan ptk7 | |
EA201992526A1 (ru) | Стабильные составы анти-ctla4 антител, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |